Why the study?
Does Interferon beta-1b therapy alter cytokine mRNA levels in peripheral mononuclear cells in patients with multiple sclerosis?
Population
31 patients with multiple sclerosis and 9 healthy controls
Comparison
Interferon beta-1b therapy vs Baseline (before therapy) and healthy controls
Design
Cohort
Follow-up
3 months
Authors
Loading...
IFN beta-1b effects in MS appear independent of sustained cytokine mRNA changes; leaves open alternative mechanisms for targeted investigation.
Does Interferon beta-1b therapy alter cytokine mRNA levels in peripheral mononuclear cells in patients with multiple sclerosis?
The therapeutic effect of IFN beta-1b in multiple sclerosis is likely not mediated by sustained changes in peripheral mononuclear cell cytokine mRNA levels.
Byskosh et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: